Research Topic: pharmacology

Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants

mycolabadmin

Researchers tested whether ketanserin, a drug that blocks serotonin receptors, could stop or reverse an LSD experience once it had already started. In a controlled study with healthy volunteers, ketanserin given one hour after LSD administration cut the duration of the LSD experience from 8.5 hours down to 3.5 hours and eliminated visual and auditory hallucinations. This finding suggests ketanserin could be useful as an emergency medication in psychedelic-assisted therapy to help patients who have negative reactions to LSD.

Read More »

Body mass index (BMI) does not predict responses to psilocybin

mycolabadmin

Researchers investigated whether a person’s body weight affects how they respond to psilocybin-assisted therapy. Analyzing 77 participants across three studies, they found that BMI did not predict how intensely people experienced the drug or how much their mental health improved afterward. This surprising finding suggests that everyone might benefit from the same fixed dose of psilocybin rather than doses adjusted to body weight, making therapy simpler and more cost-effective to deliver at scale.

Read More »

Emerging paradigms for target discovery of traditional medicines: A genome-wide pan-GPCR perspective

mycolabadmin

Traditional medicines from plants, animals, and fungi contain chemical compounds that can interact with specific proteins in our cells called G protein-coupled receptors (GPCRs). These receptors control many important body functions and are targeted by about one-third of all FDA-approved medications. This review explains how scientists are discovering new therapeutic compounds from traditional medicines by systematically screening them against the complete library of human GPCRs, using advanced techniques to identify which compounds bind to which receptors. Famous examples include morphine from poppies for pain relief and compounds from ginseng that help regulate blood sugar.

Read More »

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

mycolabadmin

This study directly compared two popular psychedelic drugs, LSD and psilocybin (magic mushrooms), in 28 healthy volunteers. Researchers found that these substances produce very similar mental effects when given at equivalent doses, with the main difference being that LSD lasts longer. The study establishes that about 20 milligrams of psilocybin is roughly equivalent to 100 micrograms of LSD. These findings could help guide dosing for future psychiatric treatments using these psychedelics.

Read More »

Sandalwood Sesquiterpene (Z)-α-Santalol Exhibits In Vivo Efficacy Against Madurella mycetomatis in Galleria mellonella Larvae

mycolabadmin

Researchers tested sandalwood compounds against a fungal infection that causes a tropical disease called eumycetoma. Using a laboratory model with wax moth larvae infected with the fungus, they found that a specific compound called (Z)-α-santalol significantly extended the survival of infected larvae. This compound was more effective than current antifungal drugs and showed promise as a potential new treatment for this neglected tropical disease.

Read More »

Bibliometric, taxonomic, and medicinal perspectives of Ganoderma neo-japonicum Imazeki: A mini review

mycolabadmin

Ganoderma neo-japonicum, known as purple Lingzhi, is a mushroom traditionally used by indigenous communities in Malaysia and other Asian countries to treat various health conditions. This review examines 36 scientific studies published between 1991 and 2021, showing that the mushroom contains special compounds that can fight cancer cells, lower blood sugar, reduce inflammation, and boost immunity. While laboratory studies show promising results, the mushroom still needs more clinical testing in humans before it can be widely used as a medicine.

Read More »
Scroll to Top